they had does dependent improvement though...which is more than avxl...
They also always noted that they would need another trial. I think its promising honestly with improvement in more objective measures despite the teasing out.
Of course one of the things they'll 'improve' is the trial duration; 12 week data was never going to be accepted for an NDA. As the PR says, next step is an 18 month study of confirmed early AD patients.